Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | GALR3 | O60755 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7602379 | 0.86 | ALDH1A1 (0.39) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL10782810 | 0.82 | TSHR (0.50) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL812118 | 0.81 | ALOX15 (0.46) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL27781433 | 0.80 | TSHR (0.43) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL27242 | 0.79 | TSHR (0.48) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL7712918 | 0.77 | ALDH1A1 (0.38) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL28607571 | 0.77 | PRKCA (0.38) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL2230506 | 0.77 | TSHR (0.46) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL9810935 | 0.76 | TSHR (0.40) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL839295 | 0.76 | TSHR (0.36) | TSHRCHRM2CHRM4CHRM1TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170281767-A1 | COMBINATION THERAPY FOR INDUCING IMMUNE RESPONSE TO DISEASE | IBC PHARMACEUTICALS, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170275375-A1 | COMBINATION THERAPY WITH T-CELL REDIRECTING BISPECIFIC ANTIBODIES AND CHECKPOINT INHIBITORS | IBC PHARMACEUTICALS, INC. | 2017-09-28 | — | — | US | disclosed |
| US-9682143-B2 | Combination therapy for inducing immune response to disease | IBC PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170021017-A1 | COMBINATION THERAPY FOR INDUCING IMMUNE RESPONSE TO DISEASE | IBC PHARMACEUTICALS, INC. | 2017-01-26 | — | — | US | disclosed |
| US-20160361360-A1 | DISEASE THERAPY WITH CHIMERIC ANTIGEN RECEPTOR (CAR) CONSTRUCTS AND T CELLS (CAR-T) OR NK CELLS (CAR-NK) EXPRESSING CAR CONSTRUCTS | IMMUNOMEDICS, INC. | 2016-12-15 | — | — | US | disclosed |
| US-20150231241-A1 | COMBINATION THERAPY FOR INDUCING IMMUNE RESPONSE TO DISEASE | IBC PHARMACEUTICALS, INC. | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150231241-A1 | COMBINATION THERAPY FOR INDUCING IMMUNE RESPONSE TO DISEASE | ICOS, IFNG, CD274 | TSHR 981/4885CHRM2 1092/4885CHRM4 1512/4885 |
| US-20170281767-A1 | COMBINATION THERAPY FOR INDUCING IMMUNE RESPONSE TO DISEASE | ICOS, IFNG, CD274 | TSHR 981/4885CHRM2 1092/4885CHRM4 1512/4885 |
| US-20170021017-A1 | COMBINATION THERAPY FOR INDUCING IMMUNE RESPONSE TO DISEASE | CD274, IFNG, CD14 | TSHR 2010/4885CHRM2 4562/4885CHRM4 4283/4885 |
| US-20160361360-A1 | DISEASE THERAPY WITH CHIMERIC ANTIGEN RECEPTOR (CAR) CONSTRUCTS AND T CELLS (CAR-T) OR NK CELLS (CAR-NK) EXPRESSING CAR CONSTRUCTS | CD74, HAVCR2, LY96 | TSHR 365/4885CHRM2 1794/4885CHRM4 2867/4885 |
| US-20170275375-A1 | COMBINATION THERAPY WITH T-CELL REDIRECTING BISPECIFIC ANTIBODIES AND CHECKPOINT INHIBITORS | CD274, IFNG, PDCD1 | TSHR 619/4885CHRM2 4201/4885CHRM4 4352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.